Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes - Wikidata - wikimedia - TriplyDB

Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes

Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes

http://www.wikidata.org/entity/Q34955621

about

Resolvins and omega three polyunsaturated fatty acids: Clinical implications in inflammatory diseases and cancer The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution Activation and resolution of periodontal inflammation and its systemic impact.High ω3-polyunsaturated fatty acids in fat-1 mice prevent streptozotocin-induced Purkinje cell degeneration through BDNF-mediated autophagy Relationship between glycemic control and histochemical myeloperoxidase activity in neutrophils in patients with type 2 diabetes Human Periodontal Stem Cells Release Specialized Proresolving Mediators and Carry Immunomodulatory and Prohealing Properties Regulated by Lipoxins Therapeutic Targets for Management of Periodontitis and Diabetes Interleukin-1 and estrogen protect against disseminating dentoalveolar infections Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms.Resolvin E1 Reverses Experimental Periodontitis and Dysbiosis.Neutrophil Resolvin E1 Receptor Expression and Function in Type 2 Diabetes.FOXO1 Regulates Bacteria-Induced Neutrophil Activity.Therapeutic Targets for Management of Periodontitis and Diabetes.Molecular basis for immunohistochemical and inflammatory changes during progression of gingivitis to periodontitis.Paradigm shift - Metabolic transformation of docosahexaenoic and eicosapentaenoic acids to bioactives exemplify the promise of fatty acid drug discovery.ERV1/ChemR23 Signaling Protects Against Atherosclerosis by Modifying Oxidized Low-Density Lipoprotein Uptake and Phagocytosis in Macrophages

P2860

Q26741524-D2FB3E18-F5C9-407A-9409-CB094255319D Q28260186-0E5C84A6-4DE4-44E3-B09E-C96983AA7D1B Q35932966-F6471055-2A84-4C5E-B7AA-E7A4C6D2B0DD Q36209582-2D8F4439-F32F-4AF8-9DD0-9BA5345F70CB Q36417045-78DE9502-C715-47DA-8ABC-19B658AA7F60 Q36440765-F6934890-A73A-475C-9384-FB18BC1D1041 Q36863273-66CC3D7C-8728-447B-9EBB-DD54EC0346A5 Q37736473-7E18A80C-EFC5-4708-9D4A-35AF6A569470 Q39088075-C3A377F2-E68D-4995-911D-C72F063C82D0 Q39471464-0BD94497-2213-4224-9D75-DBB424BF7ECF Q40403668-E9AA5023-1856-4009-A601-6FA7B23003A4 Q41468462-D583E736-E6C3-4824-BF9D-A1592D713FBA Q47121974-93959591-7C63-45D4-8F48-8E490CF9C2BD Q50193589-9A0A6DE3-1648-45AE-843E-45C803F17673 Q52369219-5351D8B4-DDBA-4AA2-BD6B-42605885E6F5 Q59135574-7586D9EC-4AA6-4E11-BC9E-2232A930B0E7

P2860

Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes

http://www.wikidata.org/entity/Q34955621

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes

@ast

Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes

@en

Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes

@nl

type

label

Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes

@ast

Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes

@en

Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes

@nl

prefLabel

Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes

@ast

Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes

@en

Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes

@nl

P1433

Q34955621-F9AFCC0B-302D-44E5-8928-FB3FEF6F9D39

P1476

Q34955621-9371B620-1CCB-4F8E-ACE2-A3AC0DB4CB23

P2093

Q34955621-2582D483-C974-41D3-9BA9-E7F0FDF493C1

Q34955621-62FCFCC1-2E71-4B51-9A61-699DD12EDDD0

Q34955621-657F5F87-1ADE-416C-B3BF-A09520701143

Q34955621-73714263-0F11-4771-88F1-47C553E77F82

Q34955621-7E72BE0E-8414-484C-8132-D02AA312FC09

Q34955621-F9A04D97-5163-4F8A-879A-48273C7800D2

P2860

Q34955621-01D95B10-933D-4E08-8353-D6B9118C2A04

Q34955621-03BE8F26-83F7-45BA-BB8B-39CDF6B74418

Q34955621-04A1DCA9-5AD0-4956-9D52-7BB835687496

Q34955621-050EC5BD-216A-4BFE-AA50-01AF460FFFE7

Q34955621-0842BAD0-032B-45A5-93A4-B5BED0C94AA1

Q34955621-0BEB759B-7AF5-4265-A030-D3693D818CD5

Q34955621-1576180A-F5E9-40C4-89D0-74156E6BA224

Q34955621-16F87A1B-299A-40E7-8AB2-B836D028F7D7

Q34955621-1F526D37-DEDB-4F66-85F7-DDF1746562EF

Q34955621-1F7F1C19-3493-45EE-B3D1-885BB5656012

P304

Q34955621-9EF177E6-DB7D-49B2-BB29-FBFACA411C43

P31

Q34955621-D75AB274-C6A3-445A-B8D7-1D1D33E07F92

P356

Q34955621-83D53E82-88DD-43DC-81A2-BA5EF21A19DC

P407

Q34955621-40B2B46C-F1CE-4398-ACF0-338536B57085

P433

Q34955621-93C52C6E-9C32-4882-84EE-DFE59808D429

P478

Q34955621-CBDCEFB8-F1D1-422A-9E21-2A2C08773324

P50

Q34955621-9A992AB5-B5A8-47BB-A3AA-49D9AB022751

P577

Q34955621-4E472AD7-85FA-4960-B465-F1C4C0A62367

P698

Q34955621-1246696A-A3FD-4889-A2F0-ED724336A9BA

P921

Q34955621-02422719-4803-42C2-8B2E-939B6D4153E7

Q34955621-ECCE6DCB-08CC-487D-A938-EF76258FFA88

P932

Q34955621-0E737664-F827-4160-B20B-91E28291438A

P356

P1433

Infection and Immunity

P1476

Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes

@en

P2093

Alpdogan Kantarci

http://www.w3.org/2001/XMLSchema#string

Bruno S Herrera

http://www.w3.org/2001/XMLSchema#string

Hatice Hasturk

http://www.w3.org/2001/XMLSchema#string

Olivia Nguyen

http://www.w3.org/2001/XMLSchema#string

Shevali Kansal

http://www.w3.org/2001/XMLSchema#string

Thomas E Van Dyke

http://www.w3.org/2001/XMLSchema#string

P2860

Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1

Platelet-neutrophil conjugate formation is increased in diabetic women with cardiovascular disease

Atherosclerosis: the new view

RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis

Resolvin D1 binds human phagocytes with evidence for proresolving receptors

Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis

Impaired phagocytosis in localized aggressive periodontitis: rescue by Resolvin E1

Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators

Nonresolving inflammation

Resolvin E1 and protectin D1 activate inflammation-resolution programmes

P304

792-801

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/IAI.02444-14

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P50

Marcelo O. Freire

P577

2014-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25486994

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4294250

http://www.w3.org/2001/XMLSchema#string